{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T05:03:38Z","timestamp":1726463018837},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T00:00:00Z","timestamp":1376265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.bjid.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:17Z","timestamp":1375315217000},"page":"1-7","source":"Crossref","is-referenced-by-count":8,"title":["Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study"],"prefix":"10.1016","volume":"18","author":[{"given":"Karina Mota","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Martin","family":"Biscione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateus Rodrigues","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle Pessoa","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirceu Bartolomeu","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Una\u00ed","family":"Tupinamb\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2013.04.001_bib0005","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/01.aids.0000247578.08449.ff","article-title":"An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults","volume":"20","author":"Bartlett","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2013.04.001_bib0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudune, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0015","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-na\u00efve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2013.04.001_bib0020","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0025","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":"Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0030","first-page":"195","article-title":"An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002","volume":"39","author":"Moore","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bjid.2013.04.001_bib0035","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/QAI.0b013e31815b1291","article-title":"Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50cells\/mm3","volume":"47","author":"Porter","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bjid.2013.04.001_bib0040","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1086\/650004","article-title":"Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care","volume":"50","author":"Routman","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2013.04.001_bib0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/QAI.0b013e318230372e","article-title":"Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study","volume":"58","author":"Mugavero","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bjid.2013.04.001_bib0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.qai.0000185314.56556.c3","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials","volume":"40","author":"Nelson","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bjid.2013.04.001_bib0055","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2013.04.001_bib0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2013.04.001_bib0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0070","first-page":"1","article-title":"Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials","volume":"1","author":"Katlama","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2013.04.001_bib0075","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jcv.2009.12.022","article-title":"Factors predictive of successful darunavir\/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)","volume":"47","author":"Delaugerre","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bjid.2013.04.001_bib0080","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/aid.2010.0059","article-title":"Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks","volume":"26","author":"Willig","year":"2010","journal-title":"AIDS Res Human Retroviruses"},{"key":"10.1016\/j.bjid.2013.04.001_bib0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1468-1293.2010.00885.x","article-title":"Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study","volume":"12","author":"Young","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bjid.2012.08.022","article-title":"High rate of virologic suppression with darunavir\/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in S\u00e3o Paulo, Brazil","volume":"17","author":"Vidal","year":"2013","journal-title":"Braz J Infect Dis"},{"issue":"Suppl. 4","key":"10.1016\/j.bjid.2013.04.001_bib0095","first-page":"18269","article-title":"High viral load, previous fosamprenavir use and recent HIV diagnosis correlate with darunavir failure in salvage therapy in S\u00e3o Paulo, Brazil","volume":"15","author":"Schontag","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.bjid.2013.04.001_bib0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/135965350901400217","article-title":"Historical resistance profile helps to predict salvage failure","volume":"14","author":"Zaccarelli","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2013.04.001_bib0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3851\/IMP1753","article-title":"Predicting antiretroviral drug resistance from the latest or the cumulative genotype","volume":"16","author":"Garc\u00eda","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2013.04.001_bib0110","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1: December 2009","volume":"17","author":"Johnson","year":"2009","journal-title":"Top HIV Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0115","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease","volume":"19","author":"Hernan","year":"2008","journal-title":"Epidemiology"},{"key":"10.1016\/j.bjid.2013.04.001_bib0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/oxfordjournals.pan.a004868","article-title":"Logistic regression in rare events data","volume":"9","author":"King","year":"2001","journal-title":"Pol Anal"},{"key":"10.1016\/j.bjid.2013.04.001_bib0125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1162\/00208180152507597","article-title":"Explaining rare events in international relations","volume":"55","author":"King","year":"2001","journal-title":"Int Org"},{"year":"1999","author":"Tomz","series-title":"RELOGIT: rare events logistic regression, version 1.1","key":"10.1016\/j.bjid.2013.04.001_bib0130"},{"key":"10.1016\/j.bjid.2013.04.001_bib0135","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1468-1293.2009.00809.x","article-title":"Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations","volume":"11","author":"Bansi","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32805e8764","article-title":"Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients","volume":"21","author":"Napravnik","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2013.04.001_bib0145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0150","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1590\/S0034-89102001000600001","article-title":"Avalia\u00e7\u00e3o da ader\u00eancia aos antirretrovirais em pacientes com infec\u00e7\u00e3o pelo HIV\/AIDS","volume":"35","author":"Lignani","year":"2001","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.bjid.2013.04.001_bib0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1037\/0278-6133.26.1.40","article-title":"Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status","volume":"26","author":"Barclay","year":"2007","journal-title":"Health Psychol"},{"key":"10.1016\/j.bjid.2013.04.001_bib0160","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.amjmed.2008.05.027","article-title":"The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy","volume":"121","author":"Bra\u00f1as","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0165","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1191\/1740774504cn032oa","article-title":"Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals","volume":"1","author":"Wood","year":"2004","journal-title":"Clin Trials"},{"key":"10.1016\/j.bjid.2013.04.001_bib0170","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2013.04.001_bib0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/10543400601001535","article-title":"Missing data imputation in two phase III trials treating HIV-1 infection","volume":"17","author":"Huson","year":"2007","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.bjid.2013.04.001_bib0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/0962280206075304","article-title":"Multiple imputation: current perspectives","volume":"16","author":"Kenward","year":"2007","journal-title":"Stat Methods Med Res"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867013001591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867013001591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:01:07Z","timestamp":1715806867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867013001591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1413867013001591"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2013.04.001","relation":{},"ISSN":["1413-8670"],"issn-type":[{"type":"print","value":"1413-8670"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}